basiliximab

基本解释

Objective To study the clinical efficacy of immunosuppressive regimen with early steroid withdrawal based on basiliximab.
目的观察在应用巴利昔单抗的基础上,早期撤除激素的免疫抑制剂方案临床效果。
Conclusion Basiliximab is safe and effective induction therapy for the sensitized recipient or the second-operation recipient.
结论舒莱是强效、安全的预防急性排斥的免疫抑制剂，在致敏及二次移植受者的免疫治疗中效果满意。
Lorber MI et al. A prospective economic evaluation of basiliximab(Simulect) therapy following renal transplantation. Clin Transplant 2000; 14(5): 479-85.
无论是活体抑或尸体肾移植，与安慰剂组相比，舒莱组患者的死亡率、移植物丢失率和发生急排的比率均较低。
Results basiliximab combined with FK506 and MMF,all together with early steroid withdrawal,which could decrease the incidence of acute rejection and redu...
结论应用巴利昔单抗同时联合强有力的免疫抑制剂FK506和MMF,调整药物FK506浓度于治疗窗范围,早期撤除激素,是安全有效的方案。
In this paper,some new immunosupressants,such as mycophenolate mofetil,tacrolimus,sirolimus,daclizumab and basiliximab,were reviewed in conjunction with drug concentration monitoring.
结合治疗药物浓度监测,本文就免疫抑制药物的研究进展作一综述。